Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (1742)	2/6/2007 1:30:31 PM
From: tuck	Read Replies (1) \| Respond to of 1826

Whisper number for MOGN, which reports tomorrow. earningswhispers.com The stock has been running up into it, as Aloxi seems to be suffering less damage than the Street initially predicted from generic Zofran. I don't have hard scrip numbers, but an analyst report suggests they are relatively strong. I sold calls against my position at $18, so if something disappoints, I'm ready. If not, I have to decide if, and how, to roll up and out. Cheers, Tuck